Amid ongoing controversy, U.S. Sen. Maggie Hassan (D-N.H.) is investigating GSK for changing a preferred bronchial asthma inhaler with a so-called licensed generic at a a lot greater value with a purpose to keep away from paying Medicaid rebates.
In a letter despatched to the corporate, the lawmaker maintained that the choice to discontinue its inhaler in January 2024 has since had “life-threatening penalties for sufferers” and contributed to a spike in hospitalizations. And so Hassan known as on GSK to return the product to market and, in the meantime, requested for quite a few paperwork regarding pricing, rebates and communications with regulators.
This marks the second time in current months that GSK has angered a lawmaker over the bronchial asthma inhaler swap. In March, U.S. Sen. Elizabeth Warren (D-Mass.) requested the Workplace of Inspector Common on the U.S. Division of Well being and Human Providers to analyze GSK and accused the corporate of “outrageous profiteering” as a result of the maneuver value Medicaid practically $1 billion final 12 months.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
